Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein, et al.
Journal of clinical lipidology (2023) Vol. 17, Iss. 4, pp. 491-503
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Ashish Sarraju, Steven E. Nissen
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 487-497
Closed Access | Times Cited: 28
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Omar Mhaimeed, Zain Burney, Stacey L. Schott, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100649-100649
Open Access | Times Cited: 20
Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, et al.
American Heart Journal (2024) Vol. 274, pp. 32-45
Open Access | Times Cited: 15
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Maciej Banach, Stanisław Surma, Peter P. Tóth
Archives of Medical Science (2023)
Open Access | Times Cited: 26
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
John J.P. Kastelein, Andrew Hsieh, Mary R. Dicklin, et al.
Current Atherosclerosis Reports (2023) Vol. 26, Iss. 2, pp. 35-44
Open Access | Times Cited: 26
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 943-943
Open Access | Times Cited: 13
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
Eric Klug, Sara Llerena, Lesley Burgess, et al.
JAMA Cardiology (2024) Vol. 9, Iss. 9, pp. 800-800
Closed Access | Times Cited: 10
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
Mariko Harada‐Shiba, Michael H. Davdison, Marc Ditmarsch, et al.
Journal of Atherosclerosis and Thrombosis (2024)
Open Access | Times Cited: 9
Dyslipidemia: A Narrative Review on Pharmacotherapy
Lucas Dorneles de Oliveira, Arthur Cicupira Rodrigues de Assis, Viviane Z. Rocha, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 289-289
Open Access | Times Cited: 8
Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Wajeeh Ur Rehman, Merav Yarkoni, Muhammad Abdullah Ilyas, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 5, pp. 152-152
Open Access | Times Cited: 8
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Maya Safarova, Tia Bimal, Daniel Soffer, et al.
American Journal of Preventive Cardiology (2024) Vol. 19, pp. 100701-100701
Open Access | Times Cited: 8
High-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment: Exploring and Explaining the “U”-Shaped Curve
Alexander C. Razavi, Anurag Mehta, Vardhmaan Jain, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 12, pp. 1725-1733
Open Access | Times Cited: 16
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
François Mach, Frank L.J. Visseren, Nilo B. Cater, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 5, pp. e685-e700
Closed Access | Times Cited: 6
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Stephen J. Nicholls, Adam J. Nelson
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Closed Access
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
N. Lan, Gerald F. Watts
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Open Access
Recent Advances in the Management of Dyslipidemia: A Systematic Review
Feng Huang, Yousaf Adil, Moon Julie, et al.
Cureus (2025)
Open Access
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Federica Agnello, Salvatore Ingala, Giulia Laterra, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1251-1251
Open Access | Times Cited: 4
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias
Brett S. Mansfield, Farzahna Mohamed, Miriam Larouche, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4160-4160
Open Access | Times Cited: 4
Obicetrapib—the Rebirth of CETP Inhibitors?
Bliss Chang, Luke J. Laffin, Ashish Sarraju, et al.
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 10, pp. 603-608
Open Access | Times Cited: 4
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis
Amand F. Schmidt, Michael H. Davidson, Marc Ditmarsch, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
Nehal N. Mehta, Katerina Dangas, Marc Ditmarsch, et al.
Pharmacological Research (2023) Vol. 197, pp. 106972-106972
Open Access | Times Cited: 9
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Stephen J. Nicholls, Adam J. Nelson
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 5, pp. 375-384
Closed Access | Times Cited: 2
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Eugen Javor, David Šarčević, Arnes Rešić
Diabetology (2024) Vol. 5, Iss. 3, pp. 300-320
Open Access | Times Cited: 2
A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
Jing Zhang, Guoying Cao, Yong Huo, et al.
The Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 2
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
Naif Saad ALGhasab, Federica Fogacci, Ashot Avagimyan, et al.
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top